What are the opening hours?

Monday 9am - 6pm Tuesday 9am - 6pm Wednesday 9am - 6pm Thursday 9am - 6pm Friday 9am - 6pm Saturday 9am - 6pm Sunday 9am - 6pm

http://gxpsolutions-pharma.com/

GxP Solutions LLC, 660 Randi Lane, Hoffman Estates, IL (2026)

11/18/2024

Ensuring compliance with 21 CFR Part 11 helps maintain the integrity, reliability, and security of electronic records and signatures, which are critical for regulatory approval and inspection readiness. When evaluating your electronic systems for 21 CFR Part 11 compliance, the focus should be on assessing the systems and processes related to electronic records and electronic signatures to ensure they meet regulatory requirements.

Here is a checklist of key areas to review:

1. System Validation
a. Validation Documentation: Ensure the system used for managing electronic records and signatures has been validated.
b. Validation Protocols: Review protocols for testing system functionality, security, and performance.
c. Change Control: Verify that any changes to the system are validated and documented.

2. Security Controls
a. Access Control: Confirm that the system restricts access to authorized personnel only.
b. Unique User IDs: Ensure every user has a unique ID and password to access the system.
c. Password Management: Check password strength policies (e.g., complexity, expiration, reuse restrictions).
d. Account Lockout: Verify account lockout policies for multiple failed login attempts.

3. Audit Trails
a. Audit Trail Activation: Ensure audit trails are enabled for all critical actions.
b. Capturing Key Information: Audit trails should capture the date, time, user ID, and details of the action performed.
c. Tamper-Proof: Verify that audit trails cannot be altered or deleted by users.
d. Review and Reporting: Ensure audit trails are reviewed periodically and can be exported for analysis.

4. Electronic Signatures
a. Signature Uniqueness: Confirm electronic signatures are unique to each individual.
b. Binding Signatures: Verify that signatures are permanently linked to their respective records.
c. Identity Verification: Review processes to ensure the identity of the signatory is verified.
d. Signature Manifestation: Confirm that electronic signatures include the printed name of the signer, the date and time, and the purpose of the signature.

5. Record Integrity
a. Data Integrity: Ensure records cannot be modified or deleted without proper authorization and documentation.
b. Backup and Recovery: Verify the existence of robust backup and recovery processes to prevent data loss.
c. Readability and Accessibility: Confirm that records remain readable, retrievable, and accessible throughout their retention period.

6. System Security
a. System Integrity: Assess measures to prevent unauthorized access, such as firewalls, antivirus software, and encryption.
b. Incident Management: Review policies for handling security breaches or data corruption.
c. Physical Security: Check physical controls for servers, workstations, and other hardware hosting the electronic systems.

14. Common Pitfalls to Avoid
a. Purchased validations from a vendor, typically do not include a 21 CFR Compliance Assessment. You will have to perform this activity yourself or contact us at [email protected].
b. Make sure the purchased validation complies with your companies’ policies and procedures.
c. Using systems that lack proper validation or security controls.
d. Poor management of passwords or shared user accounts.
e. Inadequate or incomplete audit trails.
f. Failing to periodically review and update SOPs, training, and validation protocols.
g. Neglecting vendor compliance responsibilities.

For More Information Visit
https://gxpsolutions-pharma.com/newsletter-2/

Contact us:
[email protected]

11/18/2024

Ensuring compliance with 21 CFR Part 11 helps maintain the integrity, reliability, and security of electronic records and signatures, which are critical for regulatory approval and inspection readiness. When evaluating your electronic systems for 21 CFR Part 11 compliance, the focus should be on assessing the systems and processes related to electronic records and electronic signatures to ensure they meet regulatory requirements.

Here is a checklist of key areas to review:

1. System Validation
- Validation Documentation: Ensure the system used for managing electronic records and signatures has been validated.
- Validation Protocols: Review protocols for testing system functionality, security, and performance.
- Change Control: Verify that any changes to the system are validated and documented.

2. Security Controls
- Access Control: Confirm that the system restricts access to authorized personnel only.
- Unique User IDs: Ensure every user has a unique ID and password to access the system.
- Password Management: Check password strength policies (e.g., complexity, expiration, reuse restrictions).
- Account Lockout: Verify account lockout policies for multiple failed login attempts.

3. Audit Trails
- Audit Trail Activation: Ensure audit trails are enabled for all critical actions.
- Capturing Key Information: Audit trails should capture the date, time, user ID, and details of the action performed.
- Tamper-Proof: Verify that audit trails cannot be altered or deleted by users.
- Review and Reporting: Ensure audit trails are reviewed periodically and can be exported for analysis.

4. Electronic Signatures
- Signature Uniqueness: Confirm electronic signatures are unique to each individual.
- Binding Signatures: Verify that signatures are permanently linked to their respective records.
- Identity Verification: Review processes to ensure the identity of the signatory is verified.
- Signature Manifestation: Confirm that electronic signatures include the printed name of the signer, the date and time, and the purpose of the signature.

5. Record Integrity
- Data Integrity: Ensure records cannot be modified or deleted without proper authorization and documentation.
- Backup and Recovery: Verify the existence of robust backup and recovery processes to prevent data loss.
- Readability and Accessibility: Confirm that records remain readable, retrievable, and accessible throughout their retention period.

6. System Security
- System Integrity: Assess measures to prevent unauthorized access, such as firewalls, antivirus software, and encryption.
- Incident Management: Review policies for handling security breaches or data corruption.
- Physical Security: Check physical controls for servers, workstations, and other hardware hosting the electronic systems.

Common Pitfalls to Avoid
- Purchased validations from a vendor, typically do not include a 21 CFR Compliance Assessment. You will have to preform this activity yourself or contact us at [email protected].
- Make sure the purchased validation complies with your companies policies and procedures.
- Using systems that lack proper validation or security controls.
- Poor management of passwords or shared user accounts.
- Inadequate or incomplete audit trails.
- Failing to periodically review and update SOPs, training, and validation protocols.
- Neglecting vendor compliance responsibilities.

For More Information Visit
https://gxpsolutions-pharma.com/newsletter-2/

Contact us:
[email protected]

06/16/2024

How to Audit a RABS (Restricted Access Barrier Systems) isolators for GMP (Good Manufacturing Practices)

The process involves thorough assessment to ensure compliance with regulatory requirements and industry standards. Here’s a structured approach you can follow:

Step 1 - Pre-Audit Preparation
A - Review Documentation: Obtain and review relevant SOPs (Standard Operating Procedures), validation documents, maintenance records, and any previous audit reports related to the RABS isolators.

B - Regulatory Requirements: Familiarize yourself with local regulatory requirements (e.g., FDA, EMA, WHO GMP guidelines) and company-specific GMP standards that apply to RABS isolators.

C - Audit Checklist: Prepare a comprehensive checklist covering key aspects such as design qualification (DQ), installation qualification (IQ), operational qualification (OQ), performance qualification (PQ), maintenance, cleaning procedures, and training records.

Step 2 - On-Site Audit
A - Physical Inspection:
- Verify the physical condition of the RABS isolators including cleanliness, integrity of barriers, seals, and filters.
- Ensure that the isolator setup meets design specifications and complies with GMP requirements for preventing contamination.

B - Operational Checks:
- Observe the operation of the isolators during routine production or simulated conditions.
- Check the functionality of control systems, pressure differentials, airflow patterns, and alarm systems.

C- Documentation Review:
- Examine records of maintenance activities, calibration of instruments, and periodic validation reports.
- Confirm that cleaning procedures are documented, validated, and followed rigorously.

D - Training and Competency:
- Review training records to ensure that personnel operating the RABS isolators are adequately trained and understand their responsibilities.
- Assess the competency of operators in responding to deviations and emergencies.

For More Information Visit: https://lnkd.in/gUjjRV9C --> Resources --> Newsletters
Join our Newsletter: https://lnkd.in/d8nJzTzN

04/15/2024

What are the Adverse Event Reporting Requirements Based on Good Pharmacovigilance Practices (GVP) Module VI

In Good Pharmacovigilance Practices (GVP) Module VI, adverse event reporting is a crucial aspect of ensuring the safety of medicinal products. Here's an overview of adverse event reporting based on GVP Module VI:

1. Definition of Adverse Event (AE) and Serious Adverse Event (SAE): GVP Module VI typically provides definitions for adverse events and serious adverse events. An adverse event is any untoward medical occurrence associated with the use of a medicinal product, while a serious adverse event is an event that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

2. Reporting Requirements: Module VI outlines the requirements for reporting adverse events to regulatory authorities, such as the FDA in the USA. This includes the timeframe within which adverse events must be reported, typically emphasizing the importance of timely reporting, especially for serious adverse events.

3. Format and Content of AE Reports: Guidelines are provided regarding the format and content of adverse event reports submitted to regulatory authorities. This includes the information that should be included in the report, such as details about the patient, the medicinal product(s) involved, the adverse event itself, and any actions taken in response to the event.

4. Electronic Reporting: Module VI may also address electronic reporting requirements, emphasizing the increasing use of electronic systems for the submission of adverse event reports. This includes specifications for electronic data formats and transmission methods.

5. Follow-up Reporting: Guidance is provided on follow-up reporting, which may include providing additional information about reported adverse events as it becomes available, as well as reporting on the outcome of any actions taken in response to the events.

6. Global Harmonization: GVP Module VI may also emphasize the importance of global harmonization in adverse event reporting, encouraging consistency in reporting requirements and procedures across different regulatory jurisdictions.

7. Training and Compliance: Pharmaceutical companies are typically required to ensure that personnel involved in adverse event reporting are adequately trained and comply with the reporting requirements outlined in GVP Module VI.

For More Information Join our Newsletter:
www.gxpsolutions-pharma.com

04/03/2024

ICH E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide - Explained

ICH E2B(R3) is a guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guideline is focused on the standardization of the format, content, and structure of individual case safety reports (ICSRs) for the electronic transmission of safety information for medicinal products, particularly for adverse events (AEs) and adverse drug reactions (ADRs).

Here's a breakdown of what ICH E2B(R3) entails:

Electronic Transmission of Safety Information: The guideline focuses on facilitating the electronic exchange of safety information between regulatory authorities, pharmaceutical companies, and other stakeholders involved in pharmacovigilance.

Standardized Format and Content: ICH E2B(R3) specifies the standard format and content for individual case safety reports. This standardization aims to improve consistency, accuracy, and efficiency in reporting and analyzing safety data.

Structured Data Elements: The guideline defines a set of structured data elements that should be included in individual case safety reports. These elements typically cover information such as patient demographics, medical history, details of the adverse event, suspected medicinal product(s) involved, concomitant medications, and outcome.

Data Exchange Standards: ICH E2B(R3) also outlines data exchange standards to ensure interoperability between different information systems used by stakeholders involved in pharmacovigilance. These standards help streamline the process of transmitting and processing safety information.

Support for Electronic Submission: The guideline supports the electronic submission of individual case safety reports to regulatory authorities and other relevant parties. Electronic submission offers advantages such as faster processing, improved data quality, and reduced administrative burden compared to traditional paper-based methods.

Overall, ICH E2B(R3) plays a crucial role in enhancing the efficiency and effectiveness of pharmacovigilance activities by promoting standardized electronic reporting and exchange of safety information for medicinal products.

Visit: gxpsolutions-pharma.com
[Join our newsletter]

03/21/2024

How to Perform Clinical Trial Source Data Verification (SDV)

Performing Source Data Verification (SDV) in a clinical trial involves comparing the data recorded on the Case Report Form (CRF) or electronic equivalent (e.g., eCRF) with the original source documents to ensure accuracy, reliability, and compliance with regulatory requirements.

The aim of SDV is to look for three (3) things:
1) Data errors
2) Procedural errors
3) Fraud

Here's a step-by-step guide on how to perform SDV:
1) Understand the Protocol: Before starting SDV, thoroughly familiarize yourself with the study protocol. Understand the inclusion/exclusion criteria, study endpoints, and procedures outlined in the protocol.

2) Training: Ensure that the personnel responsible for SDV are adequately trained on the protocol, data collection methods, and regulatory requirements. This training should include understanding the importance of SDV, identification of source documents, and the correct procedure for verification.

3) Identify Source Documents: Source documents are the original records or certified copies of original records that contain the data required by the protocol. Common source documents include medical records, laboratory reports, imaging results, and patient diaries. Clearly identify which documents serve as the source for each data point collected.

4) Develop a Plan: Develop a detailed SDV plan that outlines which data points will be verified, the frequency of verification, and the method of documentation. The plan should be consistent with regulatory requirements and sponsor expectations.

5) Perform Verification: Conduct SDV according to the plan. This involves physically comparing the data recorded on the CRF with the corresponding information in the source documents. Ensure that the data in the CRF accurately reflects what is documented in the source documents. Common data points for verification include demographic information, medical history, laboratory values, and adverse events.

6) Document Findings: Document all findings from the SDV process, including any discrepancies between the CRF and source documents. Clearly note any deviations from the protocol or issues with data quality.

7) Resolve Discrepancies: If discrepancies are identified during SDV, follow the procedures outlined in the protocol and standard operating procedures (SOPs) for resolving discrepancies. This may involve further investigation, clarification from the site personnel, or corrections to the CRF.

8) Ensure Compliance: Throughout the SDV process, ensure compliance with applicable regulatory requirements, including Good Clinical Practice (GCP) guidelines and local regulations.

For additional information, visit https://lnkd.in/gUjjRV9C, and go to the Resources Tab --> News Letters.

03/13/2024

How To Implement Decentralized Clinical Trials

Implementing decentralized clinical trials (DCTs) involves leveraging digital health technologies and adapting trial processes to enable remote participation and reduce the need for physical site visits [1].

Here are some steps to consider when implementing decentralized clinical trials:

Planning and Design:
Strategically plan and design the trial to incorporate decentralized elements. Consider factors such as the target patient population, trial endpoints, and data collection methods [1].

Technology Infrastructure:
Invest in appropriate digital and remote monitoring technologies that enable remote data collection, virtual visits, and telemedicine. These technologies should ensure data security and compliance with regulatory requirements[1][4].

Patient Recruitment and Informed Consent:
Develop effective strategies for remote patient recruitment and informed consent processes. Provide clear, easily understandable information about the trial, risks, benefits, and privacy protection. Utilize electronic consent methods [1][3].

Study Operations:
Streamline trial processes and adapt them for remote participation. This includes home drug delivery, remote patient monitoring through wearables or mobile health apps, and virtual study visits. Prioritize patient-centricity and aim to provide a seamless experience for participants [1][2].

Data Collection and Management:
Establish robust systems for collecting, managing, and analyzing remote patient data. Implement mechanisms to ensure data integrity, security, and privacy. Adhere to applicable regulations and guidelines [1].

Site Collaboration and Training:
Collaborate with investigational sites to ensure proper implementation of the trial protocol. Provide comprehensive training on remote trial processes, use of technology, and adherence to ethical and regulatory considerations [1][2].
....

For additional information go to gxpsolutions-pharma.com

GxP Solutions LLC

11/18/2024

11/18/2024

06/16/2024

04/15/2024

04/03/2024

03/21/2024

03/13/2024

Address

Opening Hours

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Category

Monday	9am - 6pm
Tuesday	9am - 6pm
Wednesday	9am - 6pm
Thursday	9am - 6pm
Friday	9am - 6pm
Saturday	9am - 6pm
Sunday	9am - 6pm